Xiidra is a prescription eye drop used to treat dry eye disease. Specifically, it’s FDA-approved to address both the signs (measurable damage to the eye’s surface) and symptoms (the discomfort you actually feel) of the condition. It works differently from older dry eye treatments and artificial tears, targeting the underlying inflammation rather than simply adding moisture to the eye.
How Xiidra Treats Dry Eye Disease
Dry eye disease isn’t just about not producing enough tears. In many cases, inflammation on the surface of the eye creates a self-reinforcing cycle: immune cells called T cells become activated, migrate to the eye’s surface, and release inflammatory signals that damage tear-producing tissue, which triggers more inflammation. Xiidra interrupts this cycle by blocking two proteins on cell surfaces from locking together. When these proteins can’t connect, T cells have a harder time activating and traveling to the eye’s surface. The result is a reduction in the inflammatory process driving the disease.
This mechanism is distinct from cyclosporine-based drops (the active ingredient in Restasis and Cequa), which also target inflammation but through a different pathway. Cyclosporine works by directly suppressing T-cell proliferation. Xiidra instead prevents T cells from getting the activation signal in the first place. Both approaches reduce inflammation, but they do so at different steps in the immune response. Some patients who don’t respond to one may respond to the other.
How Well It Works
Xiidra was evaluated in four clinical trials before FDA approval. In the two largest studies (OPUS-2 and OPUS-3), patients rated their eye dryness on a 0-to-100 scale before and after 12 weeks of treatment. Those using Xiidra improved 8 to 12 points more than those using placebo drops.
To put that in more practical terms: in OPUS-2, 80% of patients on Xiidra achieved at least a 10-point improvement in their dryness score after 12 weeks, compared to 63% on placebo. For a larger, 20-point improvement, 71% of Xiidra patients hit that mark versus 51% on placebo. The OPUS-3 trial showed similar patterns, with 81% achieving at least a 10-point improvement compared to 72% on placebo. These numbers mean Xiidra clearly outperforms placebo, though a significant portion of patients also improve with placebo drops alone, which is common in dry eye studies.
How Long It Takes to Work
Xiidra is not an instant fix. Some patients notice improvement in as little as two weeks, but for many it takes longer. The full effect typically develops over 6 to 12 weeks of consistent use. This timeline can feel frustratingly slow, especially if you’re dealing with daily discomfort, but it reflects the time needed to calm the inflammatory cycle rather than simply coat the eye with moisture. If you haven’t noticed any change after 12 weeks, it’s reasonable to discuss alternatives with your eye doctor.
Common Side Effects
The most frequently reported side effects occur in 5% to 25% of users:
- Irritation at the drop site, typically a stinging or burning sensation right after putting in the drops
- An unusual taste in the mouth, often described as metallic or bitter, caused by the drops draining through the tear ducts into the back of the throat
- Temporarily reduced visual clarity right after application
Less common side effects, reported in 1% to 5% of patients, include blurred vision, eye redness, headache, increased tearing, eye discharge, itching, and sinus irritation. The taste disturbance is the side effect patients mention most often. It typically passes within a few minutes. Pressing gently on the inner corner of your eye after putting in the drop can help keep the solution from draining into your throat and reduce the taste issue.
How Xiidra Compares to Other Options
For mild dry eye, artificial tears and lifestyle changes (humidifiers, screen breaks, omega-3 supplements) are usually the first step. These approaches add moisture but don’t address inflammation. When symptoms persist despite regular use of artificial tears, prescription anti-inflammatory drops like Xiidra or cyclosporine-based products become the next consideration.
Xiidra and cyclosporine target different inflammatory pathways, so choosing between them often comes down to individual response and tolerability. Xiidra may produce noticeable symptom relief somewhat faster, with some patients feeling improvement at two weeks, while cyclosporine drops often require several months before the full benefit is clear. On the other hand, cyclosporine has a longer track record and is available in generic form, which can affect cost. Neither is universally better; both are tools for the same condition that work through different biological routes.
What to Expect When Using Xiidra
Xiidra comes in single-use vials. You use one drop in each eye, twice a day, roughly 12 hours apart. Each vial is meant to be used once and then discarded, even if some solution remains. If you wear contact lenses, you’ll need to remove them before putting in the drops. You can reinsert them after about 15 minutes.
Because the drops can temporarily blur your vision, it’s worth timing your doses for moments when you won’t immediately need sharp eyesight. Many people find a morning and evening routine works well. Consistency matters: because Xiidra works by gradually reducing inflammation over weeks, skipping doses regularly can delay or diminish results. Unlike artificial tears, which provide relief on demand, Xiidra is a maintenance treatment designed for ongoing daily use.